23 October 2026
Biogaran v. Lundbeck and the Challenger’s Burden in Second Medical Use Cases
12 October 2026
Compulsory licence on a patent application: an idea making its way
6 October 2026
Plausibility and the right of priority: the French court faces apixaban
5 October 2026
Preliminary injunctions and patent applications: the French fault line
4 October 2026
Dosage inventions and inventive step: the strict reading of the French court
3 October 2026
Pharmaceutical patents and the UPC: is the Court hostile to them?
15 September 2026
Pay-for-delay: the CJEU confirms Teva/Cephalon and defines the limits of patent settlement agreements
11 September 2026
La saisie-contrefaçon, l’arme française que les titulaires étrangers oublient
10 September 2026
The launch letter before the UPC: preventing urgency for generics and biosimilars
5 September 2026
Portfolio strategy and the UPC: where the value of life sciences assets lies
5 September 2026
Merz v. Viatris on appeal: urgency remains decisive, but not every signal is urgent
4 September 2026
UPC and life sciences: the first strategic lessons
3 September 2026
Imminent infringement before the UPC: the new geography of pharmaceutical risk
30 July 2024
Sanofi v Amgen: the UPC’s first revocation action and the patentability of therapeutic antibodies, from revocation to reversal
24 July 2024
Sanofi vs. Amgen: Successful first UPC revocation action and strict assessment of therapeutic antibodies patentability
25 July 2023
APIXABAN case in France: priority to the patent holder
26 October 2020
PEMETREXED patent infringement in France: €28 million in damages for Eli Lilly (“France is back”?)